Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment

Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment

Asparaginase (ASNase) is a biopharmaceutical for Acute Lymphoblastic Leukemia (ALL) treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to proteases, and immunogenicity. Here, ASNase encapsidation was genetically directed in bacteriophage P22-based virus-lik...

Full description

Bibliographic Details
Main Authors: Cristina Díaz-Barriga, Francisca Villanueva-Flores, Katrin Quester, Andrés Zárate-Romero, Ruben Dario Cadena-Nava, Alejandro Huerta-Saquero
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
asparaginase nanoreactors
ALL treatment
P22 virus-like particles
Online Access:https://www.mdpi.com/1999-4923/13/5/604

Internet

https://www.mdpi.com/1999-4923/13/5/604

Similar Items